Boston Scientific stock drops 35% despite strong growth and margins, signaling a buy opportunity.

Boston Scientific's stock has fallen over 35% in six months, mainly due to market concerns about slowing growth. However, the company continues to show strong fundamentals with double-digit revenue growth at a 15.1% CAGR over five years and 28% operating margins. Key growth drivers include advancements in electrophysiology, the WATCHMAN CHAMPION trial, and strategic mergers and acquisitions, which could sustain an 11% EPS growth rate. While risks involve potential revenue and earnings slowdown and reliance on core products, successful trial outcomes and M&A execution may lead to significant stock upside, making it a compelling buy opportunity.